Zerviate (Cetirizine)
Brand Names: Zerviate
Methodology & AI Transparency ⓘ
Zerviate (Cetirizine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Zerviate and registered by Harrow Eye, LLC, this histamine-1 receptor antagonist product delivers active moiety Cetirizine (cross-referenced at /meds/cetirizine-hydrochloride) (2.4 mg/mL For Solution; 10mg Tablet).
- 2 Real-world patient consensus: Zerviate links directly to generic Cetirizine (/meds/cetirizine-hydrochloride) under FDA SPL 2025-05-01 (NDC 82667-015).
- 3 Typical cash cost range: Dispensing cost comparison spans $535.85 mail/discount cash up to $1420.00 uninsured retail (federal NADAC $7.3243).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Zerviate (Cetirizine) include pruritus (3.6%), nausea (7.3%), headache (7.6%).
Ask our AI Specialists anything about Zerviate (Cetirizine)
Zerviate (Cetirizine) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Zerviate and registered by Harrow Eye, LLC, this histamine-1 receptor antagonist product delivers active moiety Cetirizine (cross-referenced at /meds/cetirizine-hydrochloride) (2.4 mg/mL For Solution; 10mg Tablet). Federal labeling (2025-05-01, RxCUI 1014678-B82667015) defines its therapeutic scope: Perennial Allergic Rhinitis: Cetirizine hydrochloride is indicated for the relief of symptoms associated with perennial.
Inside Zerviate, Cetirizine mediates histamine-1 receptor antagonist pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (2.4 mg/mL For Solution; 10mg Tablet). Commercial labeling registered by Harrow Eye, LLC (SPL 2025-05-01, RxNorm 1014678-B82667015) pairs standardized excipient stability with federal price transparency metrics ($7.3243/unit NADAC; $1420.00 retail average).
Following administration (2.4 mg/mL For Solution), Zerviate (Cetirizine) achieves Estimated 73%–85% oral systemic absorption for Zerviate (Cetirizine) bioavailability and peak plasma concentration (tmax) reached 1–4 hours post-dose for zerviate (cetirizine) onset, governed by a Approximately 9–22 hours terminal plasma half-life for Zerviate (Cetirizine) terminal half-life through phase i/ii hepatic conjugation of zerviate (cetirizine) coupled with glomerular and tubular renal excretion.
Before initiating Zerviate (Cetirizine) at 2.4 mg/mL For Solution, clinical safety checklists rule out known hypersensitivity to cetirizine or structurally related histamine-1 receptor antagonist compounds; concomitant contra-labeled cyp/transporter therapies during active zerviate (cetirizine) administration. Logged tolerability patterns center on headache (7.6% of reports), nausea (7.3% of reports), dizziness (6.4% of reports).
Avoid overlapping histamine-1 receptor antagonist prescriptions alongside Zerviate (Cetirizine) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Zerviate (Cetirizine) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Cetirizine or structurally related histamine-1 receptor antagonist compounds
- Concomitant contra-labeled CYP/transporter therapies during active Zerviate (Cetirizine) administration
Logged Side-Effect Incidence (16 Reports)
Zerviate (Cetirizine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zerviate (Cetirizine))
Human clinical trial evidence for Zerviate (Cetirizine) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Zerviate (Cetirizine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $7.3243/unit (~$219.73/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1420.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $535.85 / mo | View logs ↓ |
Zerviate (Cetirizine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zerviate (Cetirizine) RxNorm Concept ID | 1014678-B82667015 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $7.3243 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1420.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $535.85 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zerviate (Cetirizine) Patient Community, Cohort Filters & Dosage Logs
Deterministic Zerviate (Cetirizine) reference combining NIH RxNorm (1014678-B82667015), Medicaid NADAC ($7.3243/unit), and anonymous cohort outcomes (74% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zerviate (Cetirizine) community threads and patient logs by age, biological sex, dosage, and treatment duration.